UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-A/A

POST-EFFECTIVE AMENDMENT NO. 2

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

Vericel Corporation

(Exact name of registrant as specified in its charter)

94-3096597
(IRS Employer
Identification Number)
02139
(Zip Code)
Name of each exchange on which
each class is to be registered
NASDAQ
(g) of the Exchange Act and is effective pursuant to General Instruction
(

Explanatory Note

This Form 8-A/A is filed by Vericel Corporation (the "Registrant"), to supplement and amend the information set forth on the Form 8-A filed by the Registrant on August 12, 2011.

Item 1. Description of Registrant's Securities to be Registered

On February 11, 2021, the Registrant and Continental Stock Transfer & Trust Company, as rights agent (the "Rights Agent"), entered into an Amendment No. 2 (the "Amendment") to the Shareholder Rights Agreement, dated as of August 11, 2011, between the Registrant and the Rights Agent (the "Rights Agreement") filed as Exhibit 4.1 to the Registrant's Registration Statement on Form 8-A filed with the Securities and Exchange Commission on August 12, 2011.

The Amendment accelerates the expiration of the Registrant's preferred share purchase rights (the "Rights") under the Rights Agreement to 5:00 p.m., New York, New York time, on February 11, 2021. Consequently, the Rights Agreement terminated at that time. At the time of the termination of the Rights Agreement, all Rights distributed to holders of the Registrant's common stock pursuant to the Rights Agreement expired.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 4.3 to this registration statement.

Item 2. Exhibits.

Exhibit	
No.	Description
3.1	Certificate of Designation, Preferences and Rights of Aastrom Biosciences, Inc. classifying and designating the Series A Junior
	Participating Cumulative Preferred Stock, filed as Exhibit 3.1 to the Registrant's Registration Statement on Form 8-A on August 12,
	2011, and is incorporated herein by reference.
<u>4.1</u>	Shareholder Rights Agreement, dated as of August 11, 2011, between Aastrom Biosciences, Inc. and Continental Stock Transfer &
	Trust Company, as Rights Agent, filed as Exhibit 4.1 to the Registrant's Registration Statement on Form 8-A on August 12, 2011, and
	is incorporated herein by reference.
4.2	Amendment No. 1 to Shareholder Rights Agreement, dated as of March 9, 2012, between Aastrom Biosciences, Inc. and Continental
	Stock Transfer & Trust Company, as Rights Agent, filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K on March 9,
	2012, and is incorporated herein by reference.
4.3	Amendment No. 2 to Shareholder Rights Agreement, dated as of February 11, 2021, between the Registrant and Continental Stock
	Transfer & Trust Company, as Rights Agent, filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K on February 12, 2021,
	and is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2021

VERICEL CORPORATION

/s/ Sean C. Flynn

By: Sean C. Flynn
Vice President, General Counsel & Secretary